Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) shares dropped 6.6% during mid-day trading on Wednesday . The company traded as low as $14.00 and last traded at $14.06. Approximately 67,075 shares were traded during trading, a decline of 68% from the average daily volume of 211,837 shares. The stock had previously closed at $15.06.
Wall Street Analysts Forecast Growth
MAZE has been the topic of a number of recent research reports. Wedbush initiated coverage on Maze Therapeutics in a report on Tuesday. They set an "outperform" rating and a $17.00 price objective on the stock. Guggenheim reissued a "buy" rating and set a $19.00 price objective on shares of Maze Therapeutics in a report on Wednesday, April 2nd. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $23.50.
Check Out Our Latest Research Report on Maze Therapeutics
Maze Therapeutics Price Performance
The business has a 50-day moving average price of $11.46.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.39).
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. General Catalyst Group Management LLC bought a new position in Maze Therapeutics during the first quarter valued at approximately $11,405,000. Bessemer Group Inc. purchased a new stake in Maze Therapeutics during the first quarter valued at about $5,305,000. Matrix Capital Management Company LP purchased a new stake in Maze Therapeutics during the first quarter valued at about $27,373,000. Nuveen LLC purchased a new stake in Maze Therapeutics during the first quarter valued at about $125,000. Finally, Invesco Ltd. purchased a new stake in Maze Therapeutics during the first quarter valued at about $226,000.
Maze Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
Featured Articles
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
